Cargando…

Evaluating the activity of temsirolimus in neuroendocrine cancer

Detalles Bibliográficos
Autores principales:	O'Donnell, P H, Ratain, M J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360210/ https://www.ncbi.nlm.nih.gov/pubmed/17164757 http://dx.doi.org/10.1038/sj.bjc.6603513

Ejemplares similares

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

Comment on ‘Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review'
por: Broderick, J M, et al.
Publicado: (2014)

Medical education, the COVID-19 pandemic, and infection prevention: There has never been a better time
por: Cheng, C., et al.
Publicado: (2022)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus
por: Briggs, Joseph W., et al.
Publicado: (2017)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Primary neuroendocrine carcinoma of breast
por: Singh, Sunita, et al.
Publicado: (2011)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Happy hypoxemia, or blunted ventilation?
por: Ora, Josuel, et al.
Publicado: (2021)

Home-based SARS-CoV-2 lateral flow antigen testing in hospital workers
por: Downs, Louise O, et al.
Publicado: (2021)

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
por: Kaley, Thomas J., et al.
Publicado: (2020)

In Reply
por: Lacouture, Mario E, et al.
Publicado: (2022)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Potentials of post-mortem CT (PMCT) in paediatric cases related to SARS-CoV-2 infection
por: Filograna, Laura, et al.
Publicado: (2023)

Neuroendocrine tumors and conotruncal cardiac defects
por: Martínez-Quintana, Efrén, et al.
Publicado: (2018)

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
por: Zardavas, Dimitrios, et al.
Publicado: (2011)

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
por: Pulido, Marina, et al.
Publicado: (2018)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Mediastinum primary small cell neuroendocrine carcinoma
por: Wang, Hong-Lu, et al.
Publicado: (2016)

Neuroendocrine tumor of the small intestine: case report
por: KAMEI, Douglas Jun, et al.
Publicado: (2020)

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
por: JURADO, JOSÉ MIGUEL, et al.
Publicado: (2013)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Squamous Cell Carcinoma and Neuroendocrine Carcinoma Colliding in the Esophagus
por: Dias, André Roncon, et al.
Publicado: (2010)

Factors associated with COVID-19 vaccine hesitancy amongst refugees in Australia
por: Liddell, Belinda J., et al.
Publicado: (2021)

Antimicrobial overuse in COVID-19 – reasons to remain vigilant as we approach the winter ‘twindemic’
por: Lowry, J., et al.
Publicado: (2023)

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
por: Wang, Li, et al.
Publicado: (2010)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010)

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
por: Le Tourneau, C, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4qqccgm66nu4n0jd2ash29f9sc